ArticleChemistry & biodiversity2026
Comparative Study on Physicochemical Characteristics and Synergistic Anticancer Effects of Polysaccharides from Different Sources of Radix Bupleuri.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Radix Bupleuri polysaccharides (RBPs) show synergistic antitumor effects with chemotherapy, but source variation causes inconsistent quality and activity. To evaluate the physicochemical properties and synergistic antitumor activity of RBPs from different species and origins, eight batches from five Bupleurum species were analyzed. Results showed varied physicochemical properties across batches. Polysaccharides from Bupleurum Chinese DC. (BCD) and Bupleurum bicaule Helm (BBH) contained the highest levels of GalA, and Rha, while those from Bupleurum marginatum Wall.ex DC. (BMW), Bupleurum falcatum L. (BFL), and Bupleurum marginatum var. stenophyllum (Wolff) Shan et Y.Li (BMS) were rich in Glc. In combination with cisplatin (DDP), RBPs from BCD showed the strongest synergistic inhibition on Huh7 and A549/DDP cell proliferation. Pearson analysis indicated that Rha and GalA positively correlated with antitumor enhancement, whereas Glc showed a negative effect, suggests that monosaccharide composition is associated with synergistic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.